ANALYST RECOMMENDATIONS : TJX, Humana, Constellation Brands, Ross Stores, W.W. Grainger...

Every day, find a selection of analysts' recommendations covering North America and the UK. The list only includes companies that have been the subject of a change of opinion or price target, or of a new coverage. It may be updated during the session. This information is used to shed light on the movements of certain stocks or the market sentiment on a company.

 

• ArcBest: Goldman Sachs maintains neutral rating and raised the target to $100 from $90.
• Ares Management: UBS raised the target to $82 from $68. Maintains buy rating.
• Axonics: Piper Sandler adjusts price target to $82 from $77. Reiterates overweight rating.
• Burlington Stores: Goldman Sachs starts at buy with $183 price target.
• Chemed: RBC Capital Markets maintains outperform rating. PT down 12% to $541.
• Chesapeake Energy:  Benchmark Company LLC initiated coverage with a recommendation of buy. PT up 52% to $137.
• Comstock Resources: Piper Sandler raised the recommendation to neutral from underweight. PT up 8.1% to $17.
• Constellation Brands: BMO Capital Markets initiated coverage with a recommendation of outperform. PT up 19% to $290.
• Humana: Morgan Stanley raised the target to $494 from $453. Maintains equal-weight rating.
• Idex: Mizuho Securities Co Ltd raised the target to $205 from $190. Maintains neutral rating.
• Man Group: Numis Securities cut the recommendation to hold from add. PT set to 275 pence.
• Matson: Stifel downgrades to hold from buy. PT up 1.9% to $93.
• Mohawk Industries: RBC Capital Markets maintains underperform rating. PT down 21% to $101.
• Ross Stores:  Goldman Sachs reinstated coverage with a recommendation of buy. PT up 24% to $102.
• TJX: Goldman Sachs reinstated coverage with a recommendation of neutral. PT set to $70.
• T. Rowe Price Group: BMO Capital Markets cut the target to $115 from $135. Maintains market perform rating.
• Visteon: Morgan Stanley maintains equal-weight rating. PT up to $107 from $91.
• WW Grainger: Oppenheimer & Co raised the target to $615 from $580. Maintains outperform rating.